PHAP I Antibody

• Catalog Number: orb1239865
• Category: Antibodies
• Description: PHAP I Antibody
• Species/Host: Rabbit
• Clonality: Polyclonal
• Tested applications: ELISA, ICC, IF, WB
• Reactivity: Human, Mouse, Rat
• Isotype: IgG
• Immunogen: Anti-PHAP I antibody (orb1239865) was raised against a peptide corresponding to 15 amino acids near the carboxy terminus of human PHAP I. The immunogen is located within the last 50 amino acids of PHAP I.
• Antibody Type: Primary Antibody
• Concentration: 1 mg/mL
• Form/Appearance: Liquid
• Conjugation: Unconjugated
• MW: Predicted: 29kDObserved: 29 kD
• Target: ANP32A
• UniProt ID: P39687
• NCBI: P39687
• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Buffer/Preservatives: PHAP I Antibody is supplied in PBS containing 0.02% sodium azide.
• Alternative names: PHAP I Antibody: LANP, MAPM, PP32, HPPCn, PHAP1, P
• Note: For research use only
• Expiration Date: 12 months from date of receipt.

Western Blot Validation in Human Raji Cell Lysate. Loading: 15 µg of lysates per lane. Antibodies: PHAP I orb1239865 (A: 2 µg/mL, B: 4 µg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Independent Antibody Validation (IAV) via Protein Expression Profile in Cell Lines. Loading: 15 µg of lysates per lane. Antibodies: PHAP I orb1239865 (2 µg/mL), PHAP I orb1239868 (1 µg/mL), and beta-actin (1 µg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Western Blot Validation in Human Cell Lines. Loading: 15 µg of lysates per lane. Antibodies: PHAP I orb1239865 (2 µg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Immunofluorescence Validation of PHAP I in Raji Cells. Immunofluorescent analysis of 4% paraformaldehyde-fixed Raji Cells labeling PHAP I with orb1239865 at 10 µg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).

Immunocytochemistry Validation of PHAP I in Raji Cells. Immunocytochemical analysis of Raji cells using anti-PHAP I antibody (orb1239865) at 2 µg/ml. Cells was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.

KD Validation of PHAPI in Human Breast Cancer Cells (Schafer et al., 2006). Human Breast Cancer Cells (T47D cells) were transfected with control or PHAPI siRNA duplex. PHAPI was detected via Western Blot analysis by using the anti-PHAPI antibody. PHAPI expression was reduced after PHAPI siRNA knockdown.

Increased Expression Validation of PHAPI in Patient Samples of BreastTumor Tissue (Schafer et al., 2006). PHAPI was overexpressed in all breast tumor samples of patients and human breast cancer cells (MDA-MB-453), but not in the normal breast tissue or human primary mammary epithelial cells (HMEC).

Overexpression of PHAPI in Breast Cancer Cells (Schafer et al., 2006). Western blot analysis with anti-PHAPI antibodies was performed for PHAPI in human cell lines from breast, prostate and lung. PHAPI was overexpressed in breast cancer cells when compared with normal cells (HMEC) whereas there were no significant differences in PHAPI expression in normal and cancer cells of either prostate or lung origin.

Induced Expression Validation of PHAPI/Anp32a in Atxn1 KO Mice (Sa´nchez et al., 2013). Western blot analysis of PHAPI/Anp32a from the cerebellum of WT and Atxn1 KO mice. PHAPI expression was significantly increased (2 folds) in Atxn1 KO mice as compared to WT mice. The same effect was observed in PHAPI mRNA levels.